Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.
Biologic product approvals in 20231 ran the gamut, including 2 new therapies to treat hemophilia A, a gene therapy for pediatric Duchenne muscular dystrophy, and the first orally administered fecal microbiota product to treat recurrent C difficile infection. And on December 8, the FDA approved 2 new therapies—the first of their kind—to treat sickle cell disease, an inherited blood disorder that disproportionately affects Black or African American individuals.
Navigating Ethical, Financial Considerations When Delivering Cancer Care
April 30th 2024“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.
FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
April 29th 2024The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.